Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial

Fineline Cube Apr 30, 2026
Company Drug

Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations

Fineline Cube Apr 30, 2026
Policy / Regulatory

Sichuan Health Commission Issues Directive to Strengthen Oversight of External Prescriptions

Fineline Cube Jan 19, 2024

The Health Commission of Sichuan Province has issued a notification aimed at enhancing the management...

Company Deals Hospital

Shaanxi Panlong Pharmaceutical Partners with Xi’an Medical University for Multifaceted Collaboration

Fineline Cube Jan 19, 2024

Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864), a leading pharmaceutical company based in China,...

Company Drug

Tasly Pharmaceuticals Gets NMPA Go-Ahead for Clinical Trial of Stem Cell Therapy in Heart Failure

Fineline Cube Jan 19, 2024

Tasly Pharmaceuticals (SHA: 600535), a leading pharmaceutical company in China, has announced that it has...

Company Drug

Sinocelltech Granted NMPA Approval for Phase I Clinical Trial in Hematological Malignancies

Fineline Cube Jan 19, 2024

Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has announced that it...

Company Drug

Sanofi’s Dupixent Receives FDA Label Update for Atopic Dermatitis Patients with Hand or Foot Involvement

Fineline Cube Jan 19, 2024

Sanofi (NASDAQ: SNY) has been granted authorization by the US Food and Drug Administration (FDA)...

Company Drug

Luzhu Biotechnology’s LZ901 Herpes Zoster Vaccine Trial Fully Enrolls 26,000 Participants

Fineline Cube Jan 19, 2024

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading manufacturer of human vaccines and therapeutic...

Company Deals

Danaher Corporation to Establish Northern China Headquarters in Beijing’s Changping District

Fineline Cube Jan 19, 2024

The Changping District People’s Government of Beijing Municipality has entered into a strategic cooperation agreement...

Company Deals

Glorious Med and Illumina Join Forces for Advanced Urinary Tract Infection Detection

Fineline Cube Jan 19, 2024

Hangzhou-based Glorious Med, a premier company specializing in gene detection for urinary system tumors, has...

Company Drug

CARsgen Therapeutics’ CT041 Shows Promising Results in Advanced Solid Tumors at ASCO GI 2024

Fineline Cube Jan 19, 2024

China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...

Company Medical Device

Ultrasound Biotechnology Earns FDA Nod for Disposable Endoscopic Ultrasound Probes

Fineline Cube Jan 19, 2024

Ultrasound Biotechnology, the Shanghai-based wholly owned subsidiary of US firm Ultrasound Wondering, Inc., has announced...

Company Deals Digital

Meinian Onehealth Collaborates with Huawei Cloud and Runda Medical on AI Health Robot

Fineline Cube Jan 19, 2024

Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with...

Company Deals

Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer

Fineline Cube Jan 19, 2024

Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors...

Company Drug

Beijing Aosaikang Initiates Phase III Trial for Advanced Gastric Cancer Treatment

Fineline Cube Jan 18, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion

Fineline Cube Jan 18, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a...

Company Drug

FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia

Fineline Cube Jan 18, 2024

Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...

R&D

Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection

Fineline Cube Jan 18, 2024

Researchers at Guangzhou’s Sun Yat-sen University Cancer Center have made a significant breakthrough with the...

Company Drug

Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy

Fineline Cube Jan 18, 2024

NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...

Policy / Regulatory

Hainan Province Unveils Measures to Support Innovative Drugs and Medical Devices Development

Fineline Cube Jan 18, 2024

Hainan provincial bureaus, including the Healthcare Security Administration (HSA), Healthcare Commission, and Medical Products Administration,...

Legal / IP Policy / Regulatory

Shanghai Medical Products Administration Issues Trial Measures for Pharmaceutical Quality and Safety Personnel

Fineline Cube Jan 18, 2024

The Shanghai medical products administration has released the “Measures for the Management of Key Quality...

Company Legal / IP

USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo

Fineline Cube Jan 18, 2024

In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...

Posts pagination

1 … 406 407 408 … 659

Recent updates

  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
  • 3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal
  • Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline
  • Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial
  • Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength

Company

3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal

Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Company Drug

Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.